TD Cowen upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $97, up from $90. The firm thinks the company has entered a renewed growth cycle, driven by TAVR indication expansion, reinforced Sapien durability from the seven-year PARTNER 3 results, and accelerating momentum with Evoque. TD sees a path to sustained double-digit organic growth for Edwards.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $108 from $104 at Goldman Sachs
- Becton Dickinson price target raised to $215 from $210 at Stifel
- Edwards Lifesciences price target raised to $105 from $100 at Stifel
- Edwards Lifesciences price target raised to $94 from $92 at Evercore ISI
- Edwards Lifesciences receives FDA approval for SAPIEN M3 mitral valve system